1. Generics Bulletin
  2. >>Legal & IP

CSPs to cost Canada C$392 million a year

 
• By Aidan Fry

Two-year certificates of supplementary protection (CSPs) will cost Canadians C$392 million (US$302 million) per year, according to an analysis conducted by the office of the country’s Parliamentary Budget Officer (PBO). CSPs were introduced in Canada under the terms of the country’s Comprehensive Economic and Trade Agreement (CETA) with the European Union (EU).

Two-year certificates of supplementary protection (CSPs) will cost Canadians C$392 million (US$302 million) per year, according to an analysis conducted by the office of the country’s Parliamentary Budget Officer (PBO). CSPs were introduced in Canada under the terms of the country’s Comprehensive Economic and Trade Agreement (CETA) with the European Union (EU).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin

US Bill Recap: Senate Judiciary Committee Offers Fresh Start For Reintroduced Off-Patent Drug Bills

 
• By Urtė Fultinavičiūtė

The US Senate Judiciary Committee’s Chairman Chuck Grassley criticized the Senate’s reduced working hours as six previously introduced bills once again land on their desk.

Jazz Agrees To Fork Out $145m To Resolve Most Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Jazz has agreed a nine figure settlement agreement in the US with purchasers of its Xyrem blockbuster following claims that it illegally delayed generic competition to the blockbuster treatment for narcolepsy via patent-litigation settlement agreements with several ANDA sponsors.

Missing BsUFA Revenue Trigger Could Open US FDA Staff To Criminal Penalty

 
• By Derrick Gingery

Massive layoffs and the biosimilar user fee program’s historic flirtation with the non-user fee spending requirements raise concerns that the FDA could lose its ability to collect BsUFA revenue, which could mean a fine or jail time for agency staff.